PMID- 24717351
OWN - NLM
STAT- MEDLINE
DCOM- 20150223
LR  - 20211021
IS  - 1522-1598 (Electronic)
IS  - 0022-3077 (Print)
IS  - 0022-3077 (Linking)
VI  - 112
IP  - 1
DP  - 2014 Jul 1
TI  - Selective modulation of GABAergic tonic current by dopamine in the nucleus 
      accumbens of alcohol-dependent rats.
PG  - 51-60
LID - 10.1152/jn.00564.2013 [doi]
AB  - The nucleus accumbens (NAcc) is a key structure of the mesolimbic dopaminergic 
      reward system and plays an important role in mediating alcohol-seeking behaviors. 
      Alterations in glutamatergic and GABAergic signaling were recently demonstrated 
      in the NAcc of rats after chronic intermittent ethanol (CIE) treatment, a model 
      of alcohol dependence. Here we studied dopamine (DA) modulation of GABAergic 
      signaling and how this modulation might be altered by CIE treatment. We show that 
      the tonic current (I(tonic)) mediated by extrasynaptic gamma-aminobutyric acid type A 
      receptors (GABA(A)Rs) of medium spiny neurons (MSNs) in the NAcc core is 
      differentially modulated by DA at concentrations in the range of those measured 
      in vivo (0.01-1 muM), without affecting the postsynaptic kinetics of miniature 
      inhibitory postsynaptic currents (mIPSCs). Use of selective D1 receptor (D1R) and 
      D2 receptor (D2R) ligands revealed that I(tonic) potentiation by DA (10 nM) is 
      mediated by D1Rs while I(tonic) depression by DA (0.03-1 muM) is mediated by D2Rs 
      in the same MSNs. Addition of guanosine 5'-O-(2-thiodiphosphate) (GDPbetaS) to the 
      recording pipettes eliminated I(tonic) decrease by the selective D2R agonist 
      quinpirole (5 nM), leaving intact the quinpirole effect on mIPSC frequency. 
      Recordings from CIE and vehicle control (CIV) MSNs during application of D1R 
      agonist (SKF 38393, 100 nM) or D2R agonist (quinpirole, 2 nM) revealed that SKF 
      38393 potentiated I(tonic) to the same extent, while quinpirole reduced I(tonic) 
      to a similar extent, in both groups of rats. Our data suggest that the selective 
      modulatory effects of DA on I(tonic) are unaltered by CIE treatment and 
      withdrawal.
CI  - Copyright (c) 2014 the American Physiological Society.
FAU - Liang, Jing
AU  - Liang J
AD  - Division of Oral Biology and Medicine, School of Dentistry, University of 
      California, Los Angeles, California; and Department of Molecular and Medical 
      Pharmacology, David Geffen School of Medicine, University of California, Los 
      Angeles, California.
FAU - Marty, Vincent N
AU  - Marty VN
AD  - Division of Oral Biology and Medicine, School of Dentistry, University of 
      California, Los Angeles, California; and.
FAU - Mulpuri, Yatendra
AU  - Mulpuri Y
AD  - Division of Oral Biology and Medicine, School of Dentistry, University of 
      California, Los Angeles, California; and.
FAU - Olsen, Richard W
AU  - Olsen RW
AD  - Department of Molecular and Medical Pharmacology, David Geffen School of 
      Medicine, University of California, Los Angeles, California.
FAU - Spigelman, Igor
AU  - Spigelman I
AD  - Division of Oral Biology and Medicine, School of Dentistry, University of 
      California, Los Angeles, California; and igor@ucla.edu.
LA  - eng
GR  - AA-016100/AA/NIAAA NIH HHS/United States
GR  - AA-017991/AA/NIAAA NIH HHS/United States
GR  - AA-07680/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140409
PL  - United States
TA  - J Neurophysiol
JT  - Journal of neurophysiology
JID - 0375404
RN  - 0 (Dopamine Agonists)
RN  - 0 (Receptors, Dopamine D1)
RN  - 0 (Receptors, Dopamine D2)
RN  - 0 (Receptors, GABA-A)
RN  - 0 (Thionucleotides)
RN  - 146-91-8 (Guanosine Diphosphate)
RN  - 20OP60125T (Quinpirole)
RN  - 67287-49-4 (2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine)
RN  - 71376-97-1 (guanosine 5'-O-(2-thiodiphosphate))
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology
MH  - Alcoholism/*metabolism/physiopathology
MH  - Animals
MH  - Dopamine/*pharmacology
MH  - Dopamine Agonists/*pharmacology
MH  - Guanosine Diphosphate/analogs & derivatives/pharmacology
MH  - *Inhibitory Postsynaptic Potentials
MH  - Male
MH  - *Miniature Postsynaptic Potentials
MH  - Neurons/drug effects/metabolism/*physiology
MH  - Nucleus Accumbens/cytology/*metabolism/physiopathology
MH  - Quinpirole/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Dopamine D1/agonists
MH  - Receptors, Dopamine D2/agonists
MH  - Receptors, GABA-A/metabolism
MH  - Thionucleotides/pharmacology
PMC - PMC4064388
OTO - NOTNLM
OT  - ethanol
OT  - neuroadaptation
OT  - tonic current
OT  - ventral striatum
OT  - withdrawal
EDAT- 2014/04/11 06:00
MHDA- 2015/02/24 06:00
PMCR- 2015/07/01
CRDT- 2014/04/11 06:00
PHST- 2014/04/11 06:00 [entrez]
PHST- 2014/04/11 06:00 [pubmed]
PHST- 2015/02/24 06:00 [medline]
PHST- 2015/07/01 00:00 [pmc-release]
AID - jn.00564.2013 [pii]
AID - JN-00564-2013 [pii]
AID - 10.1152/jn.00564.2013 [doi]
PST - ppublish
SO  - J Neurophysiol. 2014 Jul 1;112(1):51-60. doi: 10.1152/jn.00564.2013. Epub 2014 
      Apr 9.